IDEAYA Biosciences Nominates IDE034 as a Development Candidate Under Partnership with Biocytogen
Shots:
- IDEAYA Biosciences has selected IDE034, a first-in-class B7H3/PTK7 topo-I-payload bispecific ADC, as a development candidate and exercised its option to secure exclusive global rights from Biocytogen for this program
- In exchange for global rights, IDEAYA will make an upfront payment & option exercise fees plus additional development, regulatory & commercial milestones along with royalties totalling $406.5M (up to $100M development & regulatory milestones) to Biocytogen
- Furthermore, IDEAYA is planning IND submission to the US FDA in 2025 after concluding ongoing preclinical & IND-enabling trials to conduct human evaluations
Ref: IDEAYA Biosciences | Image: IDEAYA Biosciences
Related News:- IDEAYA Biosciences Collaborates with Biocytogen to Develop Bispecific ADC Program for Cancer Treatment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
